10 results on '"Hiwasa, Takaki"'
Search Results
2. Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer.
- Author
-
Sasajima, Natsuko, Sumazaki, Makoto, Oshima, Yoko, Ito, Masaaki, Yajima, Satoshi, Takizawa, Hirotaka, Wang, Hao, Li, Shu-Yang, Zhang, Bo-Shi, Yoshida, Yoichi, Hiwasa, Takaki, and Shimada, Hideaki
- Subjects
STOMACH cancer ,KREBS cycle ,AUTOANTIBODIES ,RECEIVER operating characteristic curves ,CANCER prognosis ,OVERALL survival - Abstract
The relationship between energy production and cancer is attracting attention. This study aimed to investigate the clinicopathological significance of fumarate hydratase (FH), a tricarboxylic acid cycle enzyme, in gastric cancer using autoantibodies as biomarkers. The study analyzed 116 patients who underwent gastric cancer surgery and 96 healthy controls. Preoperative serum FH autoantibody (s-FH-Ab) titers were analyzed using an immunosorbent assay with an amplified luminescent proximity homogeneous assay. Receiver operating characteristic analysis was used to determine the cutoff s-FH-Ab titer. Clinicopathological factors and prognosis were compared between the high and low s-FH-Ab groups. The s-FH-Ab levels were significantly higher in the gastric cancer group than in the control group (p = 0.01). Levels were elevated even in patients with stage I gastric cancer compared with healthy controls (p = 0.02). A low s-FH-Ab level was significantly associated with distant metastasis (p = 0.01), peritoneal dissemination (p < 0.05), and poor overall survival (p < 0.01). Multivariate analysis revealed that low s-FH-Ab levels were an independent risk factor for poor prognosis (p < 0.01). Therefore, s-FH-Ab levels may be a useful biomarker for early diagnosis and the prediction of prognosis in patients with gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Autoantibody in Cancer
- Author
-
Hiwasa, Takaki, Shimada, Hideaki, and Shimada, Hideaki, editor
- Published
- 2019
- Full Text
- View/download PDF
4. Novel serum autoantibodies against ß-actin (ACTB) in amyotrophic lateral sclerosis.
- Author
-
Sugimoto, Kazuo, Mori, Masahiro, Liu, Jia, Shibuya, Kazutomo, Isose, Sagiri, Koide, Mizuho, Hiwasa, Takaki, and Kuwabara, Satoshi
- Subjects
AMYOTROPHIC lateral sclerosis ,AUTOANTIBODIES ,COMPLEMENTARY DNA ,PARKINSON'S disease ,BIOMARKERS - Abstract
To identify novel biomarkers using the serological analysis of recombinant cDNA expression libraries (SEREX) method and to evaluate their clinical significance in amyotrophic lateral sclerosis (ALS). Serum of ALS patients were screened for autoantibodies using the SEREX method. The identified autoantibodies were validated by measuring their serum levels in 70 ALS patients, 60 normal controls (NC), and 62 Parkinson disease (PD) patients using the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The clinical relevance of these autoantibodies was investigated in ALS patients. SEREX identified 16 candidate antigens including β-actin (ACTB) in addition to proteasome subunit alpha type 7 (PSMA7) that we previously reported, and serum levels of antibodies against ACTB, were significantly higher in ALS patients than in NC (p < 0.001) and PD patients (p = 0.001). Moreover, serum levels of anti-ACTB antibody were higher in advanced stage ALS patients (Stage 4 on the King's ALS clinical staging) and in those with more severe disability (ALS Functional Rating Scale revised [ALSFRS-R] score < 40.5) compared to early stage (Stage 2 [2nd region involved)]) patients and those with less severe disability (ALSFRS-R score ≥ 40.5) (p = 0.003, p = 0.014). Anti-ACTB antibody levels were also negatively correlated with ALSFRS-R score (ρ = −0.409, p = 0.001), but positively correlated with clinical disease stage (ρ = 0.355, p = 0.003), and showed a weak positive correlation with disease duration (ρ = 0.294, p = 0.014). Anti-ACTB antibodies may be a potential biomarker of ALS could indicate disease severity. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas
- Author
-
Matsutani Tomoo, Hiwasa Takaki, Takiguchi Masaki, Oide Takashi, Kunimatsu Mitoshi, Saeki Naokatsu, and Iwadate Yasuo
- Subjects
Src ,SH3GL1 ,Autoantibody ,Glioma ,SEREX ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Glioma is the most common primary malignant central nervous system tumor in adult, and is usually not curable in spite of various therapeutic approaches. Clarification of the oncogenic process in its early stage is important for the diagnosis and effective therapy. Methods In the present study, we used the serological identification of antigens by recombinant cDNA expression cloning (SEREX) to explore the subtle changes of the protein expression in low-grade glioma. The levels of serum autoantibodies to the SEREX-identified glioma-related antigens were analyzed by ELISA, and the epitope site was identified using deletion mutants and overlap peptide array. Changes in the serum autoantibody levels were examined in the rat glioma model using C6 and 9 L glioma cell lines. Results We identified 31 glioma-related antigens by SEREX. Among them, the serum level of autoantibody to src-homology 3-domain GRB2-like 1 (SH3GL1) was significantly higher in patients with low-grade glioma than healthy volunteers or high-grade gliomas. The 10 amino-acids at the C-terminal were identified as the epitope site by the overlap peptide array and the ELISA using deletion mutants. The tissue expression of SH3GL1 protein increased in proportion to glioma progression. The rat glioma models confirmed the increase of anti-SH3GL1 autoantibody level in the early stage and the suppression in the late stage. Conclusion SH3GL1 may be involved in the oncogenic process of gliomas and effectively elicit an autologous antibody response in low-grade gliomas. The immunological reaction to SH3GL1 would contribute to the establishment of a novel diagnostic and therapeutic target for gliomas.
- Published
- 2012
- Full Text
- View/download PDF
6. Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.
- Author
-
Sugimoto, Kazuo, Hiwasa, Takaki, Shibuya, Kazutomo, Hirano, Shigeki, Beppu, Minako, Isose, Sagiri, Arai, Kimihito, Takiguchi, Masaki, Kuwabara, Satoshi, and Mori, Masahiro
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *AUTOIMMUNITY , *AUTOANTIBODIES , *IMMUNOGLOBULINS , *GENE expression - Abstract
Abstract Objective To identify autoantibodies using sera from ALS patients and elucidate their roles in disease pathology. Methods An immunological screening was performed with a phage expression library SEREX method using sera from 3 ALS patients to identify ALS-related autoantibodies. Levels of antibodies identified by SEREX were measured in 33 ALS patients and 30 normal controls (NCs) by AlphaLISA using recombinant non-full-length proteins. The results were then validated by ELISA using full-length proteins in 71 ALS patients, 30 NCs and 34 disease controls (DCs). The relationship between the titres and clinical profiles of ALS patients were examined. Results Four autoantibodies identified by SEREX were proteasome subunit alpha type 7 (PSMA7), vimentin, hydroxymethylbilane synthase and TBC1 domain family member 2 (TBC1D2). AlphaLISA revealed that only the anti-PSMA7 and anti-TBC1D2 levels were significantly different between the ALS and NCs groups. ELISA showed that only the levels of antibody against PSMA7, involved in protein degradation by the ubiquitin-proteasome pathway (UPP), were higher in the ALS group than both the NC (P <.01) and DC (P =.034) groups. Anti-PSMA7 levels tended to be negatively correlated with the logarithm of disease duration (P =.052) and were significantly positively correlated with the logarithm of creatine kinase levels (P =.011). The anti-PSMA7 antibody levels were different between patients with and without dysphagia (P <.01). Conclusions: Serum anti-PSMA7 antibody might be a disease-promoting factor in early-stage ALS and might be a biomarker of ALS. Anti-PSMA7 autoantibody might contribute to the pathogenesis of ALS, possibly via its role in the UPP. Graphical abstract Unlabelled Image Highlights • We identified antibodies against PSMA7 in sera from ALS patients by SEREX. • SEREX is an ideal method for identifying antigens of patients with motor neuron diseases and other immune-related diseases. • The titres were apparently higher in ALS patients than in normal controls and diseases controls. • Anti-PSMA7 autoantibody might contribute to the pathogenesis of ALS, possibly via its role in the UPP. • Serum anti-PSMA7 antibody might be a disease-promoting factor in early-stage ALS and might be a biomarker of ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Prognostic and diagnostic significance of preoperative Jumonji domain‑containing 6 antibodies in colorectal cancer.
- Author
-
Yoshida, Kimihiko, Hiwasa, Takaki, Ito, Masaaki, Ushigome, Mitsunori, Takizawa, Hirotaka, Li, Shu-Yang, Zhang, Bo-Shi, Iwadate, Yasuo, Funahashi, Kimihiko, and Shimada, Hideaki
- Subjects
- *
COLORECTAL cancer , *CARCINOEMBRYONIC antigen , *RECEIVER operating characteristic curves , *IMMUNOGLOBULINS - Abstract
Jumonji domain-containing 6 (JMJD6) protein has been reported to be upregulated in different cancer cells; however, to the best of our knowledge, no report has analyzed serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with cancer. Therefore, the present study evaluated the clinical significance of s-JMJD6-Abs in patients with colorectal cancer. Preoperative serum samples were analyzed from 167 patients with colorectal cancer who underwent radical surgery between April 2007 and May 2012. The pathological stages were as follows Stage I (n=47), stage II (n=56), stage III (n=49) and stage IV (n=15). In addition, 96 healthy participants were analyzed as controls. s-JMJD6-Abs were analyzed by amplified luminescent proximity homology assay-linked immunosorbent assay. The cutoff value of s-JMJD6-Abs for detecting colorectal cancer was calculated to be 5,720 using the receiver operating characteristic curve. The positive rate of s-JMJD6-Abs was 37% in patients with colorectal cancer (61 of 167), independent of carcinoembryonic antigen or carbohydrate antigen 19-9 and p53-Abs. Clinicopathological factors and prognosis were compared between the s-JMJD6-Abs-positive group and the s-JMJD6-Abs-negative group. The s-JMJD6-Ab-positive status was significantly associated with older age (P=0.03), but was not associated with other clinicopathological variables. Regarding recurrence-free survival, the s-JMJD6-positive status was a significant poor prognostic factor in both univariate (P=0.02) and multivariate (P<0.01) analyses. Similarly, regarding overall survival, the s-JMJD6-Abs-positive status was a significant poor prognostic factor in both univariate (P=0.03) and multivariate (P=0.01) analyses. In conclusion, preoperative s-JMJD6-Abs was positive in 37% of patients with colorectal cancer and may be considered an independent poor prognostic biomarker. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea.
- Author
-
Katsumata, Yusuke, Terada, Jiro, Matsumura, Takuma, Koshikawa, Ken, Sakao, Seiichiro, Tomiyoshi, Go, Shinmen, Natsuko, Nakamura, Rika, Kuroda, Hideyuki, Nagashima, Kengo, Kobayashi, Yoshio, Kobayashi, Eiichi, Iwadate, Yasuo, Zhang, Xiao-Meng, Hiwasa, Takaki, and Tatsumi, Koichiro
- Subjects
SLEEP apnea syndromes ,CORONARY disease ,ACUTE coronary syndrome ,CARDIOVASCULAR diseases risk factors ,LOGISTIC regression analysis ,DYSLIPIDEMIA - Abstract
Biomarkers are not available for monitoring the onset and progression of coronary artery disease (CAD) in patients with obstructive sleep apnea (OSA), a major risk factor for arteriosclerotic cardiovascular diseases. This study aimed to test for correlation between circulating anti-Sorting Nexins 16 antibody (SNX16-Ab) levels, CAD history and clinical parameters of patients with OSA. Sixty-four healthy donors, 82 adults with OSA, and 96 with acute coronary syndrome (ACS) were studied. Serum samples were collected at diagnostic polysomnography in the OSA group or at the disease onset in the ACS group. Serum SNX16-Ab levels were measured by amplified luminescence proximity homogeneous assay (AlphaLISA), and correlation between SNX16-Ab levels and clinical parameters was analyzed. SNX16-Ab levels and apnea-hypopnea index (AHI) were weakly correlated. Additionally, logistic regression analyses of OSA group identified that elevated SNX16-Ab level associated with the history of CAD. Circulating SNX16-Ab could increase during CAD pathogenesis in patients with OSA. Further prospective studies are required to prove the predictive potential of SNX16-Ab level in CAD onset of patients with OSA. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome.
- Author
-
Chen, Po-Min, Ohno, Mikiko, Hiwasa, Takaki, Nishi, Kiyoto, Saijo, Sayaka, Sakamoto, Jiro, Morita, Yusuke, Matsuda, Shintaro, Watanabe, Shin, Kuwabara, Yasuhide, Ono, Koh, Imai, Masao, Inoue, Katsumi, Murai, Tatsuya, Inada, Tsukasa, Tanaka, Masaru, Kita, Toru, Kimura, Takeshi, and Nishi, Eiichiro
- Subjects
- *
ACUTE coronary syndrome , *BIOMARKERS , *AUTOANTIBODIES , *METALLOENDOPEPTIDASES , *BLOOD serum analysis , *DIAGNOSIS - Abstract
Background Biomarkers for detection of transient myocardial ischemia in patients with unstable angina (UA) or for very early diagnosis of acute myocardial infarction (AMI) are not currently available. Methods and results We performed two sequential screenings of autoantibodies elevated shortly after the onset of acute coronary syndrome (ACS), and focused on metalloendopeptidase nardilysin (NRDC) among 19 identified candidate antigens. In a retrospective analysis among 93 ACS and 117 non-ACS patients, the serum level of NRDC was significantly increased in patients with ACS compared with that in patients with non-ACS (2073.5 ± 189.8 pg/ml versus 775.7 ± 63.4 pg/ml, P < 0.0001). The area under the curve of NRDC for the diagnosis of ACS was 0.822 by the receiver operating characteristic curves analysis. In the time course analysis in 43 consecutive ACS patients (AMI: N = 35 and UA: N = 8), serum concentration of NRDC was significantly increased even in UA patients with a peak serum NRDC levels reached at admission both in AMI and UA patients. In a mouse model of AMI, we found an acute increase in serum NRDC and reduced NRDC expression in ischemic regions shortly after coronary artery ligation. NRDC expression was also reduced in infarcted regions in human autopsy samples from AMI patients. Moreover, the short treatment of primary culture of rat cardiomyocytes with H 2 O 2 or A23187 induced NRDC secretion without cell toxicity. Conclusion NRDC is a promising biomarker for the early detection of ACS, even in UA patients without elevation of necrosis markers. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
10. The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement.
- Author
-
Sugimoto, Kazuo, Mori, Masahiro, Liu, Jia, Tanaka, Satoru, Kaneko, Kimihiko, Oji, Satoru, Takahashi, Toshiyuki, Uzawa, Akiyuki, Uchida, Tomohiko, Masuda, Hiroki, Ohtani, Ryohei, Nomura, Kyoichi, Hiwasa, Takaki, and Kuwabara, Satoshi
- Subjects
- *
IMMUNOGLOBULINS , *CELL analysis , *JUDGMENT (Psychology) , *CENTRAL nervous system , *MYELIN oligodendrocyte glycoprotein - Abstract
To illustrate the accuracy of the fluorescence-activated cell sorting cell-based assay (FACS-CBA) and to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies and ascertain the optimal method for positivity judgement, referencing the findings of microscopic CBA. We tested serum anti-MOG antibodies in 57 patients with central nervous system inflammatory disorders (CIDs), 30 healthy controls (HCs), and 63 disease controls (DCs) by FACS-CBA. To assess the diagnostic performance of 2 positive judgement methods for FACS-CBA, we evaluated the ratio of positive cells (RPC) and median fluorescence intensity (MFI ratio); samples from 57 CIDs and 3 antiaquaporin-4 antibody-positive patients whose anti-MOG antibody levels were relatively high but negative by FACS-CBA were tested by microscopic CBA. Blinded to the RPC and MFI ratio results, we classified the acquired dot plot into 3 patterns—"upright," "broadband," and "oblique"—as pattern analysis. The sample with the highest RPC in CIDs was subjected to serial dilution analysis. Finally, we analyzed the clinical and laboratory data of anti-MOG antibody-positive patients in the acute phase. Referencing results by microscopic CBA and receiver-operating characteristic curve analysis, the area under the curve, sensitivity, specificity, and cutoff value were 0.952, 92%, 94%, and 1.52 for RPC and 0.931, 79%, 94%, and 6.39 for MFI ratio , respectively, suggesting the optimality of RPC for positive judgement. Titers by microscopic CBA analysis significantly correlated with RPC (P =.031). In the validation study, the positive rate of RPC for anti-MOG antibodies was 42.1% in CIDs, but 0% in HCs and DCs (both P <.001). In the pattern analysis, all anti-MOG antibody-positive patients but none of the HCs and DCs exhibited the "oblique" pattern. Serial dilution curve analysis fit a quaternary polymodal. FACS-CBA using RPC analysis for anti-MOG antibodies displayed relatively higher specificity, sensitivity, and semiquantitative property, indicating it could become another acceptable test to detect anti-MOG antibodies. Unlabelled Image • We have established the cell based assay (CBA) using FACS to detect anti-myelin oligodendrocyte glycoprotein (MOG)-IgG. • Our FACS-CBA using the ratio of positive cell (RPC) for anti-MOG-IgG displayed relatively high and specificity. • FACS-CBA using RPC for anti-MOG-IgG showed higher sensitivity than FACS-CBA using the ratio of median fulorescence intensity. • Our FACS-CBA using RPC for anti-MOG-IgG has semiquantitative property. • Patern analysis of cell imaging after smoothing can play a supportive role on judgement of positivity of anti-MOG-IgG. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.